GBC AG Initiates Coverage on Marinomed Biotech AG – Buy Recommendation with Price Target of EUR 42.00

GBC AG Initiates Coverage on Marinomed Biotech AG – Buy Recommendation with Price Target of EUR 42.00

Augsburg/Vienna, March 27, 2025 – GBC AG has initiated coverage on the Austrian biotech company Marinomed Biotech AG (ISIN: ATMARINOMED6; WKN: A2N9MM; Ticker: MARI Vienna Stock Exchange). In its initial research report, the analysts issue a Buy recommendation with a price target of EUR 42.00, representing significant upside potential compared to the closing price on March 26, 2025 (EUR 14.20).

Marinomed Biotech AG focuses on innovative pharmaceuticals for the treatment of immunological and inflammatory diseases. Following a comprehensive restructuring in 2024, including the sale of its Carragelose business to Unither Pharmaceuticals, the company is now fully focused on its patented Marinosolv® technology platform.

Technology in Focus: Marinosolv®
Marinosolv® enhances the solubility and bioavailability of poorly soluble active ingredients. The current development pipeline centers around two key products:

• Budesolv: A low-dose corticosteroid nasal spray for the treatment of allergic rhinitis (“seasonal allergies”), offering fast onset of action and a preservative-free formulation.
• Tacrosolv: An innovative eye drop formulation of the immunomodulator tacrolimus for the treatment of inflammatory eye diseases.

The pipeline is further complemented by Solv4U, a platform through which external pharmaceutical companies can access Marinosolv technology for their own drug development.

Significant Market Potential
The target indications for Budesolv and Tacrosolv are among the largest global therapeutic markets:

• The allergic rhinitis market affects more than 500 million people and continues to grow, driven by environmental factors.
• The market for inflammatory eye diseases, including dry eye and allergic conjunctivitis, is expanding due to an aging population and increasing screen time.

According to our analysts, Marinomed’s formulations address not only medical needs but also regulatory and patient demands, such as rapid efficacy, preservative-free solutions, and convenient administration – positioning the company as a relevant solution provider for potential global licensing partners.

Presentation at the 39th Munich Capital Market Conference (MKK)
On April 2, 2025, Marinomed Biotech AG will present at the 39th MKK in Munich. Institutional investors will have the opportunity to meet the management team and learn more about the company’s strategic direction.

Analyst View and Valuation
According to GBC, Marinomed is ideally positioned for a successful restart following its strategic transformation, backed by a strong IP portfolio (patent protection until at least 2043), growing market demand, and a highly scalable technology. Long-term upside is seen particularly in the licensing potential of Budesolv and Tacrosolv, as well as in monetization through Solv4U.

The full research report is available at: https://www.more-ir.de/d/32048.pdf

About Marinomed Biotech AG
Founded in 2006, Marinomed Biotech AG is a company specializing in immunology and virology, headquartered in Korneuburg, Austria. Following its strategic realignment around the Marinosolv platform, the company pursues a growth-oriented approach to commercializing novel, high-efficacy therapies for respiratory and eye diseases. The company is listed on the Vienna Stock Exchange (Open Market) as well as on most major German stock exchanges, including Frankfurt and Munich.

Disclaimer:
This press release does not constitute investment advice or a solicitation to buy or sell securities. Investments in equities are generally associated with risks – including the potential loss of the entire invested capital.

Notice on potential conflicts of interest pursuant to §85 WpHG and Art.20 MAR:
GBC AG and the responsible analyst point out that, at the time of publication, the following potential conflicts of interest may exist: 5a, 6a, 7, 11.

For full disclosure, please refer to the complete research report or visit: https://www.gbc-ag.de/de/Offenlegung

Press contact:
GBC AG
Tel.: +49 821 241133 0
Email: office@gbc-ag.de